Company: CDT
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001641172-25-010405
Chunk: 170

Company: CDT Equity Inc.
Filing Date: 2025-05-15
Form: 10-Q
Item: Part II, Item 5
Chunk 170
---
 *
    Filed
    herewith.
  
    §
    In
    accordance with Item 601(b)(32)(ii) of Regulation S-K and SEC Release Nos. 33-8238 and 34-47986, Final Rule: Management’s Reports
    on Internal Control Over Financial Reporting and Certification of Disclosure in Exchange Act Periodic Reports, the certifications
    furnished in Exhibits 32.1 and 32.2 hereto is deemed to accompany this Quarterly Report on Form 10-Q and will not be deemed “filed”
    for purposes of Section 18 of the Exchange Act. Such certification will not be deemed to be incorporated by reference into any filing
    under the Securities Act or the Exchange Act, except to the extent that the registrant specifically incorporates it by reference.

39

SIGNATURES

In
accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.

    CONDUIT
    PHARMACEUTICALS INC

    May
    14, 2025
    By:
    /s/
    Dr. Andrew Regan

    Name:
    Dr.
    Andrew Regan

    Title:
    Chief
    Executive Officer

    (Principal
    Executive Officer)

    May
    14, 2025
    By:
    /s/
    James Bligh

    Name:
    James
    Bligh

    Title:
    Interim
    Chief Financial Officer

    (Principal
    Financial and Accounting Officer)

40